Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Oragenics Inc.OGEN · healthcare
GradeNonecomputable_factors_below_threshold: 3 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $10.1M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, short runway, thin data, degenerate inputsnot computable: distress, fortress balance sheet
Inputs computable3 of 14
Graded fromfilings received through Mar 16, 2026207 days before the rescan; every figure keyed to the SEC receipt date
Last close$0.482026-10-08; market equity $2.2M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$0.5$1NovDecJanFebMarAprMayJunJulAugSepOct$0.46
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2012nonen/aQ1
Mar 21, 2014nonen/aQ2
Mar 21, 2015nonen/aQ1
Apr 21, 2019nonen/aQ2
Apr 21, 2024nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 16, 2026; the document on sec.gov.

description contains certain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from the results discussed in the forward-looking statements as a result of certain of the risks set forth herein. We assume no obligation are a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its lead product candidate, ONP-002.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 505.7%[3-4]
Short runway. cash runway is 4.5 months[5]
Thin data. 3 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 40.4
Gross profitabilitynot computable32.2%
latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(10.3%)[1,6-8](6.6%)40.48112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
annual revenue must exceed $100,000
Solvency
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-primenot computable(0.31)
latest aligned inputs end 2011-12-31; latest annual assets end 2025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
interest expense must exceed $100,000
Current rationot computable2.96x
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Growth and financing, sleeve percentile 82.6
Revenue growth, three-year compoundnot computable10.0%
four consecutive annual observations are required
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 9
Reinvestment ratenot computable37.1%
required facts have no common fiscal period end
Asset growth, three years(12.0%)[1,8-10]2.1%71.17042025-12-31
Net share issuance, one year505.7%[3-4]2.5%94.26342026-03-13

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(61.1%)8.0%10hotter than 10 of 100 peers
Distance from 52-week high(66.7%)(31.4%)13closer to its high than 13 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(735.1%)(1.0%)1pricier than 99 of 100 peers
Book value to price1.760.2895pricier than 5 of 100 peers
Sales to price0.020.318pricier than 92 of 100 peers
Composite equity issuance, five years430.5%20.3%97more equity-funded than 97 of 100 peers
Relative strength against the sector, log excess return(1.16)(0.14)10ahead of 10 of 100 peers

Inputs: market equity $2.1M; EBIT -$9.4M; free cash flow -$15.4M; book equity $3.7M; sales $37,653; cash $3.9M[11].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(668.4%)✗ fail[6,8]
Operating cash flow above zero-$9.2M✗ fail[7]
Return on assets improved(455.6 pts)✗ fail[6,8-9,12]
Operating cash flow exceeds net income$596,100✓ pass[6-7]
Long-term leverage felln/a[1,8-9]
Current ratio improvedn/a[13-14]
No new shares issued505.7%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improvedn/a[8-9]
Cash, filings, liquidity
Cash and equivalents$3.9M[5]
Operating cash flow, four quarters-$10.2M[5,7,15-18]
Months of runway4.5
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing57
10-Q received Aug 13, 2026
Median daily dollar volume$12,263
63 sessions
Days since newest grade input207

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$10.1M2025-12-312026-03-1610-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$37,6532023-12-312025-03-1410-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding4,336,0292026-03-132026-03-1610-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding21,475,2892025-03-102025-03-1410-Kfiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$3.9M2026-06-302026-08-1310-Qfiling · viewer · series
6net incomeus-gaap:NetIncomeLoss-$9.8M2025-12-312026-03-1610-Kfiling · viewer · series
7operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$9.2M2025-12-312026-03-1610-Kfiling · viewer · series
8assetsus-gaap:Assets$1.5M2024-12-312026-03-1610-Kfiling · viewer · series
9assetsus-gaap:Assets$5.0M2023-12-312025-03-1410-Kfiling · viewer · series
10assetsus-gaap:Assets$14.8M2022-12-312024-03-2910-Kfiling · viewer · series
11shares outstandingdei:EntityCommonStockSharesOutstanding4,511,9572026-08-122026-08-1310-Qfiling · viewer · series
12net incomeus-gaap:NetIncomeLoss-$10.6M2024-12-312026-03-1610-Kfiling · viewer · series
13current assetsus-gaap:AssetsCurrent$10.1M2025-12-312026-03-1610-Kfiling · viewer · series
14current assetsus-gaap:AssetsCurrent$1.5M2024-12-312026-03-1610-Kfiling · viewer · series
15operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$4.4M2026-06-302026-08-1310-Qfiling · viewer · series
16operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.2M2026-03-312026-05-0810-Qfiling · viewer · series
17operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$6.4M2025-09-302025-11-0710-Qfiling · viewer · series
18operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.4M2025-06-302026-08-1310-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.